Daniel Marbach

Roche (Switzerland) — Switzerland

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index7.8kcitations90works5.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bioinformatics and Genomic Networks(29), Gene Regulatory Network Analysis(23), Cancer Immunotherapy and Biomarkers(18), Protein Degradation and Inhibitors(17), Lung Cancer Treatments and Mutations(15)

Publications89 total

Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial
Nature Medicine·2025· 3 citedOpen Access
Comparison of single-cell RNA-seq methods to enable transcriptome profiling of neutrophils in clinical samples
Cell Reports Methods·2025· 2 citedOpen Access
A microfluidic bone marrow chip for the safety profiling of biologics in pre-clinical drug development
Communications Biology·2025· 4 citedOpen Access
Generalizable AI predicts immunotherapy outcomes across cancers and treatments
2025· 9 citedOpen Access
Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)
BMC Cancer·2025· 6 citedOpen Access
Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma
EBioMedicine·2024· 8 citedOpen Access
Comparison of Fixed Single Cell RNA-seq Methods to Enable Transcriptome Profiling of Neutrophils in Clinical Samples
2024· 8 citedOpen Access
Immune Modulation in Solid Tumors: A Phase 1b Study of RO6870810 (BET Inhibitor) and Atezolizumab (PD-L1 Inhibitor)
2024· 1 citedOpen Access
Contextual AI models for single-cell protein biology
Nature Methods·2024· 50 citedOpen Access
Supplementary Figure S2 from Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
2024Open Access
Data from Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
2024Open Access
Supplementary Results S1 from Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
2024Open Access
Supplementary Figure S1 from Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
2024Open Access
Supplementary Table S2 from Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
2024Open Access
Supplementary Table S1 from Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
2024Open Access
Supplementary Figure S1 from Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
2024Open Access
Supplementary Table S2 from Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
2024Open Access
Supplementary Methods S1 from Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
2024Open Access
Supplementary Table S1 from Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
2024Open Access
Supplementary Figure S2 from Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
2024Open Access
page 1 of 5Next →

Frequent Co-authors

Gustavo Stolovitzky(9), Dario Floreano(9), Sven Bergmann(9), Manolis Kellis(8), Claudio Mattiussi(7), Robert J. Prill(5), David Lamparter(5), Zoltán Kutalik(5), Jitao David Zhang(5), Thomas Schaffter(4), Julio Sáez-Rodríguez(4), Sarvenaz Choobdar(4), Jake Crawford(4), Mattia Tomasoni(4), Sabine Wilson(4), Iakov I. Davydov(4), Sushmita Roy(3), Leonidas G. Alexopoulos(3), Tao Fang(3), Michelle M. Li(3)